RevoDx HIV-1/2 qPCR Kit (Qualitative)

RevoDx HIV-1/2 qPCR Kit is a real-time PCR test intended for the qualitative detection of Human Immunodeficiency virus type 1 and type 2 (HIV-1/2) RNA.

RevoDx HIV-1 qPCR Kit (Quantitative)

RevoDx HIV-1 qPCR Kit is a RT-PCR test intended for quantification of Human Immuno-deficiency virus type 1 (HIV-1) RNA. 

RevoDx HIV-2 qPCR Kit (Quantitative)

RevoDx HIV-2 qPCR Kit is a RT-PCR test intended for quantification of Human Immuno-deficiency virus type 2 (HIV-2) RNA.

 

RevoDx HIV-1 qPCR Kit (Qualitative)

RevoDx HIV-1 qPCR Kit is a real-time PCR test intended for the qualitative detection of  Human Immunodeficiency virus type 1 (HIV-1) RNA. 

RevoDx HIV-2 qPCR Kit (Qualitative)

RevoDx HIV-2 qPCR Kit is a real-time PCR test intended for the qualitative detection of  Human Immunodeficiency virus type 2 (HIV-2) RNA

 

Instruments

The RevoDx HIV Products are to be used with BIO-RAD CFX96 and Tianlong Gentier 96 Real-Time PCR Detection Systems. But the RevoDx HIV Products may also be compatible with most real-time PCR detection systems with the channels FAM, HEX and ROX

 

Features

  • Validated for use with fresh or frozen human serum or plasma collected in EDTA anticoagulant.
  • Dual Targets minimize the risk of false negative test results due to the potential mutations in the target regions of the HIV-1 genome covered by the oligos 
  • For quantitative kits, Quantification Standards ranging from 1 x 104 IU/mL to 1 x 107  IU/mL
  • Exogenous internal control
  • The Limit of Detection (LoD) value is 50 IU/mL to 62 IU/mL (depending on the kit)
  • Diagnostic specificity is ≥ 99 %
  • Can detect and quantify all subtypes of HIV-1 M group and Circulating Recombinant Forms
  • Whole system failure rate is ≤1 %
  • For research use only

Product Name

Cat. No.

RevoDx HIV-1/2 qPCR Kit (Qualitative)

IP202238

RevoDx HIV-1 qPCR Kit (Quantitative)

IP201903

RevoDx HIV-2 qPCR Kit (Quantitative)

IP202237

RevoDx HIV-1 qPCR Kit (Qualitative)

IP201924

RevoDx HIV-2 qPCR Kit (Qualitative)

IP202236

Contact Us